कृपया अन्य खोज का प्रयास करें
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Mark J. Gergen | 61 | 2018 | Executive Chairman of the Board |
Cynthia L. Collins | 66 | 2021 | Independent Director |
John P. Schmid | 61 | 2018 | Lead Independent Director |
Luca Gattinoni | - | 2021 | Member of Scientific Advisory Board |
Luke David Corning | 42 | 2020 | Independent Director |
Mark A. Kay | 65 | 2023 | Member of Gene Therapy Scientific Advisory Board |
Marcea Bland Lloyd | 75 | 2019 | Independent Director |
Carl H. June | 69 | 2021 | Chairman of Cell Therapy Scientific Advisory Board |
Jan Joseph Melenhorst | - | 2021 | Member of Scientific Advisory Board |
Christine Brown | - | 2021 | Member of Scientific Advisory Board |
Julian Grunewald | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Kathryn A. Whitehead | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Ian E. Alexander | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Charles M. Baum | 66 | 2022 | Independent Director |
Rafael G. Amado | 60 | 2023 | Director |
George McDonald Church | 70 | 2022 | Chairman of Gene Therapy Scientific Advisory Board |
Mark Tracy | - | 2023 | Member of Gene Therapy Scientific Advisory Board |
Kristin Yarema | 53 | 2023 | President, CEO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है